- Home
- ZKH vs RGNX Comparison
ZKH vs RGNX Comparison
Compare ZKH & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZKH
- RGNX
- Stock Information
- Founded
- ZKH 1998
- RGNX 2008
- Country
- ZKH China
- RGNX United States
- Employees
- ZKH N/A
- RGNX N/A
- Industry
- ZKH
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZKH
- RGNX Health Care
- Exchange
- ZKH Nasdaq
- RGNX Nasdaq
- Market Cap
- ZKH 496.1M
- RGNX 424.8M
- IPO Year
- ZKH 2023
- RGNX 2015
- Fundamental
- Price
- ZKH $3.09
- RGNX $8.34
- Analyst Decision
- ZKH Buy
- RGNX Strong Buy
- Analyst Count
- ZKH 1
- RGNX 8
- Target Price
- ZKH $4.00
- RGNX $31.75
- AVG Volume (30 Days)
- ZKH 31.5K
- RGNX 769.5K
- Earning Date
- ZKH 08-21-2025
- RGNX 07-31-2025
- Dividend Yield
- ZKH N/A
- RGNX N/A
- EPS Growth
- ZKH N/A
- RGNX N/A
- EPS
- ZKH N/A
- RGNX N/A
- Revenue
- ZKH $1,217,705,644.00
- RGNX $156,718,000.00
- Revenue This Year
- ZKH $11.72
- RGNX $327.08
- Revenue Next Year
- ZKH $10.57
- RGNX N/A
- P/E Ratio
- ZKH N/A
- RGNX N/A
- Revenue Growth
- ZKH 2.24
- RGNX 80.70
- 52 Week Low
- ZKH $2.50
- RGNX $5.04
- 52 Week High
- ZKH $4.10
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- ZKH 45.88
- RGNX 47.68
- Support Level
- ZKH $2.97
- RGNX $8.51
- Resistance Level
- ZKH $3.17
- RGNX $9.27
- Average True Range (ATR)
- ZKH 0.14
- RGNX 0.50
- MACD
- ZKH -0.01
- RGNX 0.02
- Stochastic Oscillator
- ZKH 50.00
- RGNX 50.37
About ZKH ZKH Group Limited each representing thirty-five (35)
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.